According to informed sources, about half a dozen pharmaceutical companies are going to make a renewed offer to acquire the Swiss pharmaceutical company Mepha, belonging to the family of the late German billionaire Adolf Merckle. Among them will be selected by 2-3 companies, the sources said. The deal could reach more than 700 million Swiss francs (695 million U.S. dollars). Time frame for submission of final proposals are not set.
Among the bidders for the company as a major pharmaceutical producers and manufacturers of specialized generics, although the estimated potential buyers, such as France's Sanofi-Aventis, and Hungary's Gedeon Richter with offers to buy Mepha not previously performed. The U.S. generic company Watson Pharmaceuticals Inc also sat on the sidelines because of the complexity of work in Switzerland, where the approval of drugs differs from the process in the EU.
Friday, July 23, 2010
«GlaxoSmithKline» plans to reduce drug prices
British multinational corporation «GlaxoSmithKline plc» plans to significantly reduce the prices of medicines in developing markets next spring, - reported on Nov. 30 edition of the «Financial Times». The cost of drugs on them can be reduced by 2 / 3 compared with that in developed markets. Hussein Abbas (Abbas Hussain), president of the department to work in developing countries «GlaxoSmithKline», said that in his opinion, it is preferable to establish low-cost medicines in order to receive no income from the 100 units of 100 patients, but lower prices and a 100 [pc] income from 500 patients.
Takeda is interested in the Indian pharmaceutical market
Japan's largest pharmaceutical company, Takeda Pharmaceutical does not preclude the acquisition of Indian drug manufacturers, reports Financial Express. The head of Indian unit appointed Shankar Suryanarayanan, who previously worked for a Swiss company Roche and Novartis. As the President of Takeda, the Japanese company may buy the Indian pharmaceutical producers to start the generic business in developing countries. In 2008, another Japanese pharmaceutical company - Daiichi Sankyo acquired a controlling stake in India's Ranbaxy Laboratories. According to informed sources, referenced in Financial Express, Mr. Suryanarayanan conducting a study of the Indian pharmaceutical market to find larger companies to enter into partnerships or even acquire a minority stake in such companies.
Company Teva is one of the leaders in the struggle for the acquisition of Ratiopharm
As reports Bloomberg referring to informed sources, the Israeli pharmaceutical company Teva Pharmaceutical Industries Ltd. is one of the most probable candidates for the acquisition of German generic company Ratiopharm GmbH. In addition to Teva potential buyers may become Ratiopharm French Sanofi-Aventis SA and Chinese Sinopharm Group Co. Ltd. The second round of the auction ends this week. Teva representative comment on market rumors refused. According to sources, for further talks about buying Ratiopharm will be invited to 4-6 companies.
Despite the crisis, biotechnology and pharmaceuticals received a record U.S. investment
In 2008, the pharmaceutical and biotechnology companies of the United States spent a record amount on research - $ 65.2 billion, a $ 2 billion more than in 2007.
These data provide marketing firm Burrill & Company.
Of these funds, approximately $ 50.3 billion accounted for pharmaceutical, about $ 14.9 billion - biotech companies.
Investigation of Wharton Business School found that in 2006 U.S. companies operating in this market, spending on scientific research and introduction of scientific developments in the production of $ 65 thousand to each of its employees. This is about 8 times more than the level of such investments of all other sectors of the U.S. economy
These data provide marketing firm Burrill & Company.
Of these funds, approximately $ 50.3 billion accounted for pharmaceutical, about $ 14.9 billion - biotech companies.
Investigation of Wharton Business School found that in 2006 U.S. companies operating in this market, spending on scientific research and introduction of scientific developments in the production of $ 65 thousand to each of its employees. This is about 8 times more than the level of such investments of all other sectors of the U.S. economy
NINE FACTORS OF DEVELOPMENT OF CANCER
The researchers found that 35% of all deaths from cancer are due to the nine risk factors. Among them - obesity, decreased physical activity, poor fruit and vegetable diet, alcohol, urban air pollution, unsafe sex and contaminated needles, medical instruments.
Diabetics should NOT be depressed
Diabetes - this diagnosis, and life, where strict discipline is very important. Seattle researchers found that patients prone to frequent and severe depression, more than any other risk - prematurely withdraw from life. This conclusion is based on research, which was attended by 4154 people. Initially, all volunteers received a thorough medical examination, and then for three years for them under surveillance.
During these three years, died 13,6% of patients, constantly suffering from mild forms of depression. Mortality among subjects with severe depression - 11,9%.
During these three years, died 13,6% of patients, constantly suffering from mild forms of depression. Mortality among subjects with severe depression - 11,9%.
Subscribe to:
Posts (Atom)